Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1780 - A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies.


09 Sep 2017


Poster display session


Clinical Research;  Oesophageal Cancer


Takashi Kojima


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


T. Kojima1, H. Kasai2, T. Tsushima3, H. Hara4, Y. Mori5, R. Ishihara6, K. Kato7, S. Hironaka8, K. Mukai2, O. Kikuchi5, K. Enomoto2, H. Tada2, R. Uozumi2, A. Kawaguchi9, M. Muto5

Author affiliations

  • 1 Department Of Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Chiba/JP
  • 2 Institute For Advancement Of Clinical And Translational Science (iact), Kyoto University Hospital, Kyoto/JP
  • 3 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka/JP
  • 4 Department Of Gastroenterology, Saitama Cancer Center, Saitama/JP
  • 5 Department Of Therapeutic Oncology, Kyoto University Hospital, Kyoto/JP
  • 6 Department Of Gastrointestional Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka/JP
  • 7 Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 8 Clinical Trial Promotion, Chiba Cancer Center Hospital, 260-8717 - Chiba/JP
  • 9 Center For Comprehensive Community Medicine, Faculty Of Medicine, Saga University, Saga/JP


Abstract 1780


There is no effective chemotherapy for patients with esophageal squamous cell carcinoma (ESCC) refractory or intolerant to 5-FU, platinum, and taxanes. TAS-102 is an oral combination drug of trifluridine and tipiracil hydrochloride. Our preclinical study showed that TAS-102 has antitumor activity against 5-FU resistant esophageal cancer cells. We conducted this study to evaluate the safety and efficacy of TAS-102 in ESCC patients who were refractory or intolerant to standard treatment (UMIN000019268).


Patients with histologically proven advanced or recurrent ESCC, which had been refractory or intolerable to 5-FU, platinum, and taxanes, were eligible. Patients also had to satisfy following criteria: >20 years of age; ECOG performance status 0 or 1; adequate organ functions. TAS-102, 35 mg/m2 bid, was administered on days 1-5 and 8-12 for the first 2 weeks followed by 2-week rest. The regimen was repeated every 4 weeks until disease progression, serious adverse event, or refusal. Primary endpoint was progression-free survival rate at 3 months (PFS3). With expected PFS3 of 25% to 30% and the null hypothesis of 10% under 80% power and a one-sided significance level of 5%, 35 patients was needed.


A total of 42 patients were enrolled. 90% of the patients were male, 95% had distant metastasis, and 98% had target lesion (s). As of data cutoff, 34 events were observed. PFS3 was 15.4% (90% CI: 7.4%, 26.0%), which did not reject the null hypothesis. Median PFS and OS were 1.3 months and 4.5 months, respectively. Response rate was 0%, although 24% (10/42) of patients achieved stable disease. There were 3 patients not evaluable for response. Major treatment related adverse events of grade ≧3 were: neutrophil count decreased (48%), febrile neutropenia (7%), and appetite decreased (5%). No treatment related death was observed.


TAS-102 was feasible and showed modest efficacy in patients with refractory ESCC.

Clinical trial identification

UMIN000019268, 2015/10/13

Legal entity responsible for the study

Kyoto University Hospital


Taiho Pharmaceutical Co. Ltd.


T. Kojima: Corporate-sponsored research (to institution): Onoyakuhin, Shionogiseiyaku, MSD, Taihouyakuhin, Merukuserono, AstraZeneca. T. Tsushima: Takeda, Chugai Pharma, Taiho Pharmaceutical. H. Hara: AstraZeneca, Chugai Pharma, Merck Serono, MSD, Ono Pharmaceutical, Taiho. Pharmaceutical, Takeda, Boehringer Ingelheim, Dainippon Sumitomo Pharma, Daiichi-Sankyo. K. Kato: ONO Phaumaceticals, MSD, Sionogi, Merck Serono. M. Muto: Olympus, Mitsui Knowledge Industry, Taiho Pharmaceutical, Chugai Pharma, Theravalues Corporation, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.